composite

Biotech Tools & CRO Core

members 5 weighting equal benchmark SPY

Equal-weight composite of the tools/CRO tier of the biotech capital-cycle thesis: quality laggards that monetize a reopened biotech funding window without single-trial risk — instruments (TMO, DHR), contract research (MEDP), bioprocessing (RGEN), and computational chemistry (SDGR).

Cumulative return since Sep 21 — both lines start at 0%, so the gap between them IS the out/under-performance. Hover for daily values.

	1D	7D	30D	3M	1Y
cohort	-2.3%	-2.8%	-4.1%	+25.0%	+13.3%
SPY	-1.2%	-1.0%	-1.2%	+3.5%	+14.4%
Δ	-1.2%	-1.8%	-2.8%	+21.5%	-1.1%

equal-weight · buy-and-hold from window start, no rebalancing · 3M+ windows are a current-roster backcast.

30D breadth 3/5 up

trend: 4 up · 0 flat · 1 down · avg RSI 54 · 100% above SMA200 · covered 5/5

contributors

DHR+0.8pp+3.9%

MEDP+0.8pp+3.8%

TMO+0.5pp+2.7%

RGEN-0.9pp-4.3%

SDGR-5.3pp-26.4%

DHR $229.75 -1.8% +3.9% +19.4% +5.3% 59 in trend -5.4%

MEDP $653.96 -1.3% +3.8% +8.0% +19.6% 64 in trend -4.5%

TMO $676.54 -2.5% +2.7% +18.2% +19.3% 55 in trend -4.1%

RGEN $178.71 -0.7% -4.3% +29.9% +13.5% 51 in trend -10.1%

SDGR $22.60 -5.4% -26.4% +49.4% +8.7% 40 coming into play -33.1%